|
|
|
17.11.26 - 04:00
|
FOSUN PHARMA : SRT-003-1 Approved for Clinical Trial (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) (600196.SH)'s holding subsidiary Xingrui Jingxuan has received approval from the National Medical Products Administration for the clinical trial of F-SR031 injection (SRT-003-1) for positron emission tomography imaging of fibroblast activation protein-positive lesions in patients with solid tumors. Xingru......
|
|
|
|
|
13.11.26 - 11:00
|
FOSUN PHARMA Repurchases 1.4855 Million Shares for Approx. HKD24.59 Million (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced that it repurchased 1.4855 million shares on Nov 13 at a price ranging from HKD16.41 to HKD16.57 per share, involving approximately HKD24.5898 million.Since the repurchase mandate resolution was approved, the group has cumulatively repurchased 19.454 million shares, accounting for 3.6% of its is......
|
|
|
13.11.26 - 03:00
|
FOSUN PHARMA : FKC516 Initiates Phase II Clinical Trial in China (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK)'s controlling subsidiary Fosun Kaili (Shanghai) Biotechnology Co., Ltd. has initiated a Phase II clinical trial in China for FKC516 injection for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).FKC516 is a targeted CD20 autologous CAR-T cell therapy product in-licensed by t......
|
|
|
|
|
|
|
27.10.26 - 12:15
|
Results: FOSUN PHARMA 9M Net Profit RMB2.667B Up 5.71% YoY (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced its results for the first nine months ended September 2026. Revenue rose 3.64% YoY to RMB30.463 billion. Net profit increased 5.71% YoY to RMB2.667 billion, with EPS at RMB1.01.For 3Q alone, revenue rose 1.44% YoY to RMB10.02 billion. Net profit increased 15.18% YoY to RMB946 million, with EPS a......
|
|
|
21.09.26 - 12:00
|
FOSUN PHARMA Repurchases 271,500 Shares on Mon for HKD4.8623 million (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced that it repurchased 271,500 shares on September 21 at a price ranging from HKD17.78 to HKD17.98 per share, involving approximately HKD4.8623 million.(da)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the ......
|
|
|
|
|
|
|
15.09.26 - 12:00
|
FOSUN PHARMA Repurchases 1.3 million Shrs on Tue for HKD22.07 million (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced that it repurchased 1.3 million shares on September 15 at prices ranging from HKD16.89 to HKD17.1 per share, involving approximately HKD22.0707 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the au......
|
|
|
11.09.26 - 12:00
|
FOSUN PHARMA Spends HKD21.8642 million on Buyback of 1.34 million Shrs on Fri (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced that it repurchased 1.34 million shares on September 11 at prices ranging from HKD16.14 to HKD16.5 per share, involving approximately HKD21.8642 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the a......
|
|
|
|
|
|
|
|
|
|
|
03.09.26 - 11:45
|
FOSUN PHARMA 's FCN-159 New Indication Approved (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced that Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of the company, received approval from the National Medical Products Administration for the drug registration application of FCN-159 tablets, with the trade name Fumeining, for a new indication. The newly approved ......
|
|
|
|
|
25.08.26 - 19:30
|
Results: FOSUN PHARMA 1H26 Net Profit Up 1.1% YoY to RMB1.721B; No Dividend (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced its interim results for the six months ended June. Revenue rose 4.9% YoY to RMB20.377 billion. Gross profit increased 8.5% to RMB10.088 billion. Net profit amounted to RMB1.721 billion, up 1.1% YoY, with EPS of RMB0.65. No dividend was declared. (d)~AASTOCKS Financial NewsWebsite: www.aastocks.c......
|
|
|
25.08.26 - 14:48
|
Fosun Pharma Announces 2026 Interim Results (PR Newswire)
|
|
|
Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the......
|
|